Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
about
RNA vaccines in cancer treatmentHuman leukocyte-derived arginine aminopeptidase. The third member of the oxytocinase subfamily of aminopeptidasesA new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanomaEpitope mapping of the melanosomal matrix protein gp100 (PMEL17): rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartmentATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejectionIdentification of a meiosis-specific protein as a member of the class of cancer/testis antigensAntigen processing in vivo and the elicitation of primary CTL responsesHuman tumor antigens recognized by T lymphocytesA new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomasSynthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTLT cell avidity and tumor recognition: implications and therapeutic strategies.Safety of targeting tumor endothelial cell antigensAdaptive Immune Resistance: How Cancer Protects from Immune AttackTherapeutic cancer vaccines: past, present, and futureT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?DNA vaccine for cancer immunotherapyMolecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma ModelPhotodynamic therapy of tumors can lead to development of systemic antigen-specific immune responseMass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapyMelanoma Peptide Vaccines.Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteinsTumor antigens and tumor vaccines: peptides as immunogens.Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays.Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.Multiple splice variants within the bovine silver homologue (SILV) gene affecting coat color in cattle indicate a function additional to fibril formation in melanophores.Human tumor antigens for cancer vaccine development.Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progressionBioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene.Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.Strategies to overcome obstacles to successful immunotherapy of melanomaPhase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
P2860
Q21296852-F307E7E5-6880-4BC9-AF06-507752DCBD28Q24304359-8A352ED3-4F45-4E4F-9922-D78C4C99802DQ24307739-08F004A5-F0A3-4B4A-AC61-C93BF14CADF9Q24337303-0B7CCEBC-6653-4B5C-AA94-345D4338A4BCQ24531314-D45C72D4-BDD6-4ADF-85F9-8A543B7336EDQ24561706-43918B31-6314-4436-9BC2-51708E08DBB5Q24569553-CF55AD66-C203-4457-86CE-72703AEFF82FQ24675502-2091994E-E822-4D00-8139-AC49BB54A2B9Q24678508-31E4EC8D-5D79-41B7-BF67-C3883519C4D5Q24679739-36C2E18F-F34E-4824-848A-9603C4FC6184Q24684276-7D46E3F0-45E4-43B6-8C95-4C4D59D4F1BBQ24815775-8C179528-DA72-49BF-9768-B9EFF01D88ACQ26748863-A45416D9-CC9F-491D-9ED2-6068914D13BBQ26798448-97C8DA46-80ED-4800-9C9A-CD66FE668F7CQ26863283-0A4815E2-7D66-4445-8B8F-5035CBB9321FQ27335110-4BDC62BF-FDB3-4329-B17D-F40E948ADA23Q28080919-F8FD1FCE-2C5B-424D-A3EC-FE5F0068C571Q28138094-F8A92F5C-2495-49F0-8E96-5CCF378E4DCFQ28607232-D1EE585F-045C-404A-AB0F-5639626F7F96Q28744245-55194DF3-105E-497C-819C-C4960297EE96Q30304153-E963446E-D146-41D7-B8FD-18D2839242C9Q30305530-6E284A4A-FDB5-4A5F-9E48-97391B2DD998Q30305778-14A94F2F-852A-4B34-B86B-AF1229F57158Q30310231-8FD1B6DA-4AF2-483A-97B1-44673670B687Q30442847-4632BBC9-7E0E-4B68-9037-8FD2267044E9Q30469630-EA7FC872-3EE6-48EA-98DE-9C16ABE43E2BQ30894063-D45A74CE-6211-4F92-8E80-3B38CDC65F36Q31048160-2018E92A-88DC-48BB-B588-EF6F9008C861Q32142930-425A5E1D-9C57-44DD-8114-5207F7F2B3B6Q33300166-534A49B0-C5DD-4572-992B-1662E75E17B0Q33776127-D3DF4872-652B-4E16-80A8-10BFDA2D18ACQ33822591-0EB59F14-5D3E-46AE-A024-A25EE1BF8C3AQ33854375-0E83DC4F-49BF-4291-BA7B-7390C86ED79FQ33891014-E2985066-9284-4A51-BB14-CDD4E4FDDB17Q33894967-F58C01B9-418C-48D0-A8A7-BB919B51A2BFQ33909760-0A3F1D61-0FB6-4F56-9F63-37A5CBEB06EEQ34021153-527CE5F6-4CEC-4218-9C4A-F4EF9A5D12E9Q34035564-BEE2D732-8308-432C-A78E-9CF0465F4840Q34042968-FEF74EDF-469D-438F-9537-D493707BACC0Q34173622-DE94403F-E0C9-4230-8B8F-AC3ACFF85074
P2860
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Melanocyte lineage-specific an ...... umor-infiltrating lymphocytes.
@en
type
label
Melanocyte lineage-specific an ...... umor-infiltrating lymphocytes.
@en
prefLabel
Melanocyte lineage-specific an ...... umor-infiltrating lymphocytes.
@en
P2093
P2860
P356
P1476
Melanocyte lineage-specific an ...... umor-infiltrating lymphocytes.
@en
P2093
Kawakami Y
Rosenberg SA
Schreurs MW
de Boer AJ
P2860
P304
P356
10.1084/JEM.179.3.1005
P407
P577
1994-03-01T00:00:00Z